{"id":321,"date":"2020-01-14T22:56:39","date_gmt":"2020-01-14T22:56:39","guid":{"rendered":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/?post_type=press-release&#038;p=321"},"modified":"2024-05-06T23:04:21","modified_gmt":"2024-05-06T23:04:21","slug":"monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award","status":"publish","type":"press-release","link":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/","title":{"rendered":"Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit &#038; Award"},"content":{"rendered":"<p>Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit &amp; Award<\/p>\n<p>MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 14, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announce the 11 Patient Entrepreneurs chosen as finalists for the Lyfebulb-Helsinn Cancer Innovation Summit &amp; Award to be held on January 30, 2020. The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of cancer. Valerie Vanhooren, Co-founder and CEO of ONA Therapeutics has been selected as one of the finalists.<\/p>\n<p>Read full press release here:<\/p>\n<p style=\"padding-left: 40px;\"><a href=\"https:\/\/www.helsinn.com\/news-and-events\/lyfebulb-and-helsinn-announce-11-finalists-for-the-third-annual-lyfebulb-helsinn-cancer-innovation-summit-and-award\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.helsinn.com\/news-and-events\/lyfebulb-and-helsinn-announce-11-finalists-for-the-third-annual-lyfebulb-helsinn-cancer-innovation-summit-and-award\/<\/a><\/p>\n<p style=\"padding-left: 40px;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-322\" src=\"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/new03-300x249.png\" alt=\"\" width=\"300\" height=\"249\" srcset=\"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/new03-300x249.png 300w, https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/new03.png 403w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n","protected":false},"template":"","class_list":["post-321","press-release","type-press-release","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ona Therapeutics | Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit &amp; Award<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ona Therapeutics | Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit &amp; Award\" \/>\n<meta property=\"og:description\" content=\"Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit &amp; Award MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 14, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/\" \/>\n<meta property=\"og:site_name\" content=\"Ona Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-06T23:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/new03-300x249.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@onatherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/press-release\\\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\\\/\",\"url\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/press-release\\\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\\\/\",\"name\":\"Ona Therapeutics | Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/press-release\\\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/press-release\\\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/new03-300x249.png\",\"datePublished\":\"2020-01-14T22:56:39+00:00\",\"dateModified\":\"2024-05-06T23:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/press-release\\\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/press-release\\\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/press-release\\\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/new03.png\",\"contentUrl\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/new03.png\",\"width\":403,\"height\":335},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/press-release\\\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit &#038; Award\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/#website\",\"url\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/\",\"name\":\"Ona Therapeutics\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/#organization\",\"name\":\"Ona Therapeutics\",\"url\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/logo.png\",\"width\":968,\"height\":440,\"caption\":\"Ona Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/ona-therapeutics.com\\\/website_f8a3cb38\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/onatherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ona-therapeutics\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ona Therapeutics | Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/","og_locale":"en_US","og_type":"article","og_title":"Ona Therapeutics | Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award","og_description":"Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit &amp; Award MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 14, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on [&hellip;]","og_url":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/","og_site_name":"Ona Therapeutics","article_modified_time":"2024-05-06T23:04:21+00:00","og_image":[{"url":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/new03-300x249.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@onatherapeutics","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/","url":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/","name":"Ona Therapeutics | Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award","isPartOf":{"@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/#primaryimage"},"image":{"@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/#primaryimage"},"thumbnailUrl":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/new03-300x249.png","datePublished":"2020-01-14T22:56:39+00:00","dateModified":"2024-05-06T23:04:21+00:00","breadcrumb":{"@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/#primaryimage","url":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/new03.png","contentUrl":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/new03.png","width":403,"height":335},{"@type":"BreadcrumbList","@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/press-release\/monaco-principality-of-monaco-ona-therapeutics-nominated-finalist-at-third-annual-lyfebulb-helsinn-cancer-innovation-summit-award\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/"},{"@type":"ListItem","position":2,"name":"Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit &#038; Award"}]},{"@type":"WebSite","@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/#website","url":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/","name":"Ona Therapeutics","description":"","publisher":{"@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/#organization","name":"Ona Therapeutics","url":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/#\/schema\/logo\/image\/","url":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/logo.png","contentUrl":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-content\/uploads\/2024\/05\/logo.png","width":968,"height":440,"caption":"Ona Therapeutics"},"image":{"@id":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/onatherapeutics","https:\/\/www.linkedin.com\/company\/ona-therapeutics\/"]}]}},"_links":{"self":[{"href":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-json\/wp\/v2\/press-release\/321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-json\/wp\/v2\/types\/press-release"}],"wp:attachment":[{"href":"https:\/\/ona-therapeutics.com\/website_f8a3cb38\/wp-json\/wp\/v2\/media?parent=321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}